Vertex Pharmaceuticals (VRTX) reported $2.96 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 12.1%. EPS of $4.52 for the same period compares to -$12.83 a year ago.
The reported revenue represents a surprise of +2.59% over the Zacks Consensus Estimate of $2.89 billion. With the consensus EPS estimate being $4.24, the EPS surprise was +6.6%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Vertex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product revenues, net: $2.94 billion versus the 10-analyst average estimate of $2.87 billion.
- Revenues by Product- Trikafta/Kaftrio: $2.55 billion versus $2.56 billion estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +4.2% change.
- Revenues by Product- ALYFTREK: $156.8 million versus $125.61 million estimated by nine analysts on average.
- Revenues by Product- Other product revenues: $236.1 million versus $179.78 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +20.2% change.
- Other revenues: $20.7 million compared to the $10 million average estimate based on three analysts.
View all Key Company Metrics for Vertex here>>>
Shares of Vertex have returned +0.6% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
